Contingent payment obligations to noteholders
Company: Core Scientific
The claim, verbatim
If the new shares trade below plan equity value, convertible noteholders are eligible for up to $130 million in cash or stock over 3 years, up to about $43 million per year.
Source (primary)
core-scientific 8-K exhibit (d735123dex992.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-13)Live source ↗
Quote: “up to $130 million of potential Contingent Payment Obligations to the convertible noteholders (up to ~$43 million per year for 3 years)”
How we checked this
Checked on November 14, 2026. The cited source supports every part of this claim.
The document says that if the new shares trade below Plan Equity Value, convertible noteholders are eligible for up to $130 million in cash or stock over 3 years. It also describes these as Contingent Payment Obligations of up to about $43 million per year for 3 years.
Confirmed in the source:
- The payment is triggered if the company's new common shares trade below the Plan Equity Value
- Convertible noteholders are eligible for up to a total of $130 million
- Payment may be made in cash or stock
- The payments are spread over a 3-year period
- Payments are up to about $43 million per year
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312524014941/d735123dex992.htm) in full (29,831 characters, retrieved November 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d735123dex992.htm)
Quote: “up to $130 million of potential Contingent Payment Obligations to the convertible noteholders (up to ~$43 million per year for 3 years)”